Exclusive Summary

• • A Potent TYK2/JAK1 JH2 allosteric inhibitor
• • The inhibitory activity against JAK1 JH2 is significantly superior to that of Deucravacitinib.
• • The efflux ratio is low, enabling it to maintain effective concentrations for ulcerative colitis treatment at low doses.
• • The exposure and half-life is significantly improved.
• • The clinical efficacy is significantly superior to that of Deucravacitinib in PSO, IBD data of Ph1b is under evaluation.